Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors-Reference-Cited by-同舟云学术

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

Published:2015-05 Issue: Volume:20 Page:12-28
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Juchum Michael,Günther Marcel,Laufer Stefan A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference171 articles.

1. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity;Ai;Amino Acids,2014

2. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay;Arcila;Clin. Cancer Res.,2011

3. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations;Asahina;Br. J. Cancer,2006

4. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis;Assaraf;Drug Resist. Updat.,2006

5. LUX-Lung 4: a phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib;Atagi;J. Thorac. Oncol.,2011

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological insights into brain-targeted cancer therapy and bioinspired microrobots;Drug Discovery Today;2024-09

2. Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis;Frontiers in Oncology;2024-08-13

3. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor;Bioorganic Chemistry;2024-06

4. DEPDC1B is a Novel Direct Target of B-Myb and Contributes to Malignant Progression and Immune Infiltration in Lung Adenocarcinoma;Frontiers in Bioscience-Landmark;2024-05-27

5. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09